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INTRODUCTION 
 
          Subclinical hypothyroidism is defined as an elevated serum TSH 
level associated with normal total or free T4 and T3 values. The overall 
prevalence has been reported to range from 6 – 8% in women and 3% in 
men(up to 10% in women more than 60 years)1. Because of the frequency 
with which this condition  is encountered, important questions have been 
raised regarding its clinical relevance and appropriate management. 
One of the myths that surrounds subclinical hypothyroidism is that 
the laboratory profile of an elevated serum TSH and normal free thyroid 
hormone levels really represents "compensated hypothyroidism." The  
reasoning behind this idea is that, since  the circulating levels of thyroid 
hormones are within the normal range with only the serum TSH being  
elevated, the affected subject is really euthyroid  because the increased 
TSH is stimulating and driving the thyroid gland to  produce normal 
thyroid hormone levels. Certainly, elevated serum TSH  levels do 
stimulate even a diseased thyroid gland to produce and release more 
thyroid hormone. However, as long as the serum TSH level remains  
elevated, the thyroid hormone levels are not truly normal for that 
individual. The clearance kinetics of thyroid hormones and TSH from the 
circulation actually make such a conclusion inescapable. Because the 
half-life of T4 is 7 days and that of T3 is 1 day, the serum TSH, which has 
a half-life of less than 1 hour, would certainly be expected to return to 
2 
 
normal if thyroid hormone levels  were, indeed, normal for that individual. 
An elevated TSH in an individual  patient, thus, means that the circulating 
thyroid hormone concentrations are insufficient, with a few rare 
exceptions (TSH-secreting tumors, thyroid hormone resistance 
syndromes). Subclinical hypothyroidism represents mild thyroid failure 
and is a clinically important  disorder that has adverse   clinical 
consequences and that should be treated in  most, if not all, cases 2. 
The etiologies of subclinical and overt hypothyroidism are identical. 
Chronic autoimmune thyroiditis (Hashimoto's disease) accounts for the 
majority of cases. Approximately 54% of patients with subclinical 
hypothyroidism have Hashimoto's disease with high serum concentrations 
of antithyroid microsomal or antithyroid peroxidase  antibodies 3. 
Subclinical hypothyroidism may increase the risk of coronary heart 
disease (CHD) by adversely affecting cardiovascular risk factors. Despite 
some conflicting results many studies have found that subjects with 
subclinical hypothyroidism have higher total cholesterol and low-density 
lipoprotein/cholesterol levels than euthyroid subjects. A cross-sectional 
study showed that subjects with subclinical hypothyroidism have 
increased C-reactive protein values. Subclinical hypothyroidism also has 
been associated with increased risk for atherosclerosis. 
Another important concern is the progression of subclinical 
hypothyroidism to overt hypothyroidism during its natural history.Risk is 
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high if the TSH is more than 10 uIU/mL or thyroid peroxidase antibody is  
positive. In the Whickham survey  the annual risk of women developing 
hypothyroidism was 4.3% per year if both an elevated serum TSH and 
anti-thyroid antibodies were found, 2.6% with elevated TSH alone, and 
2.1% per year with positive anti-thyroid antibodies alone4.In a recent 
prospective study on the spontaneous course of  patients with subclinical 
hypothyroidism by Gerold Huber and team they concluded that risk 
factors for progression to overt hypothyroidism were base line TSH 
>12uIU/mL,decreased thyroid reserve and presence of thyroid peroxidase 
antibody 5. 
          This study mainly focuses on the clinical profile (symptoms and 
signs), etiology and lipid abnormalities of patients with subclinical 
hypothyroidism in our setting. 
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REVIEW OF LITERATURE 
SUBCLINICAL HYPOTHYROIDISM 
 
The term subclinical hypothyroidism was first introduced in the 
early 1970s coincident with the introduction of serum thyrotropin (TSH) 
measurements. This term eventually replaced other terms, such as 
preclinical myxedema, compensated euthyroidism, preclinical 
hypothyroidism, and decreased thyroid reserve.  
         Subclinical hypothyroidism is best defined as a high serum TSH 
concentration and normal serum free or total thyroxine (T4) and 
triiodothyronine (T3) concentrations associated with few or no symptoms 
or signs of hypothyroidism. Some investigators, especially those studying 
the neuropsychiatric aspects of hypothyroidism, also include patients who 
have high-normal basal serum TSH concentrations and supranormal 
serum TSH responses  to thyrotropin-releasing hormone (TRH).  
By definition, patients with subclinical hypothyroidism cannot be 
identified on the basis of symptoms and signs. Studies emphasize the 
difficulty in making the diagnosis of primary hypothyroidism using 
clinical symptoms alone; euthyroid subjects and  patients with mild or 
overt hypothyroidism all  had similar constellations of symptoms. It is 
important to note that, in Colorado study euthyroid subjects experienced a 
mean of 12.1% of all listed symptoms, overtly hypothyroid subjects had 
16.6% of these symptoms and subjects with mild thyroid failure reported 
an intermediate 13.7% of the symptoms. This suggests a “dosage effect” 
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between levels of thyroid hormones and symptoms 6. Consistent with 
these findings, a Swiss study involving 332 women with hypothyroidism 
reported that 24% of the 93 subjects with mild thyroid failure exhibited 
typical symptoms of hypothyroidism 7.  
One of the myths that surround subclinical hypothyroidism is that 
the laboratory profile of an elevated serum TSH and normal free thyroid 
hormone levels really represents “compensated hypothyroidism.” The 
reasoning behind this idea is that, since the circulating levels of thyroid 
hormones are within the normal range with only the serum TSH being 
elevated, the affected subject is really euthyroid because the increased 
TSH is stimulating and driving the thyroid gland to produce normal 
thyroid hormone levels. Certainly, elevated serum TSH levels do 
stimulate even a diseased thyroid gland to produce and release more 
thyroid hormone. However, as long as the serum TSH level remains 
elevated, the thyroid hormone levels are not truly normal for that 
individual. The clearance kinetics of thyroid hormones and TSH from the 
circulation actually makes such a conclusion inescapable. Because the 
half-life of T4 is 7 days and that of T3 is 1 day, the serum TSH, which 
has a half-life of less than 1 h, would certainly be expected to return to 
normal if thyroid hormone levels were, indeed, normal for that individual. 
An elevated TSH in an individual patient, thus, means that the circulating 
thyroid hormone concentrations are insufficient, with a few rare 
exceptions (TSH-secreting tumors, thyroid hormone resistance 
syndromes). 
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ETIOLOGY 
The causes of subclinical hypothyroidism are the same as the 
causes of overt hypothyroidism.  Most patients have chronic autoimmune 
thyroiditis, as defined by high serum concentrations of antithyroid 
peroxidase (anti-TPO) antibodies. In a Michigan outpatient practice, 54% 
of patients with subclinical hypothyroidism had chronic autoimmune 
thyroiditis, and in a community survey in Whickham, England, 67% of 
women and 40% of men with high serum TSH concentrations had high 
serum antibody values3,8. Destructive therapy for thyrotoxicosis caused 
by Graves' hyperthyroidism is another major cause of subclinical 
hypothyroidism, accounting for 39% of the cases in the Michigan study. 
Among clinically euthyroid patients who have received radioiodine 
therapy for Graves' hyperthyroidism, at least half have high serum TSH 
concentrations, and in one survey, 65% of clinically euthyroid patients 
treated surgically for Graves’ disease had high TSH 
concentrations9,10.Several drugs may cause subclinical (or overt) 
hypothyroidism, including lithium carbonate, iodine, iodine-containing 
drugs such as amiodarone, and iodine-containing radiographic contrast 
agents. Smoking may exacerbate subclinical hypothyroidism and its 
metabolic consequences11. External radiation therapy to the neck also 
may cause subclinical hypothyroidism. Another important cause of 
subclinical hypothyroidism is inadequate thyroid hormone therapy for 
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overt hypothyroidism. In a community-based study (in Framingham, 
Massachusetts), 37% of older patients taking thyroid hormone 
preparations for hypothyroidism had high serum TSH concentrations12. 
Inadequate thyroid therapy may have been intentional in some patients 
because of coexisting heart disease, but more often it is caused by poor 
patient compliance or inadequate monitoring of therapy. 
 
EPIDEMIOLOGY 
          Several population-based studies have defined the prevalence of 
subclinical hypothyroidism. In England (the Whickham Survey), the 
prevalence of serum TSH concentrations higher than 6 uIU/mL in the 
absence of overt hypothyroidism was 7.5% in women and 2.8% in men 8. 
An age-dependent increase in serum TSH was found in women only 
when those with high serum antithyroid antibody concentrations were 
included in the analysis, and not all in men. In women aged over 75 years, 
the prevalence of subclinical hypothyroidism was 17.4%. In a similar 
study in Detroit, the prevalence of high serum TSH concentrations was 
8.5% in women and 4.4% in men13. 
The higher prevalence of subclinical hypothyroidism in elderly 
patients was confirmed by data from the Framingham Study, in which the 
prevalence of minor elevations in serum TSH in patients aged over 60 
years was 8.2% in men and 16.9% in women14 and by a Dutch study in 
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which the prevalence of subclinical hypothyroidism in a group of women 
(mean age, 55 years) was 4%; the rate was 7.3% in the same group of 
women 10 years later. The prevalence of subclinical hypothyroidism may 
be lower in some elderly women; in an English study, the prevalence was 
13.7% in women aged 60 to 69 years and 6.2% in women aged over 80 
years15.Subclinical hypothyroidism is more prevalent in areas of higher, 
as compared with lower, but not deficient, iodine intake. Among nursing 
home residents with a mean age of 80 years and similar prevalence of 
high serum anti-TPO antibody concentrations, the prevalence of 
subclinical hypothyroidism was 4.2% in relatively iodine-deficient 
northern Hungary; 10.4% in Slovakia, where iodinated salt prophylaxis 
had been mandated for 40 years; and 23.9% in Eastern Hungary, where 
iodine intake is high16.Subclinical hypothyroidism is more prevalent in 
patients with Down’s syndrome, type I diabetes mellitus, and probably 
other autoimmune diseases. In a survey of pregnant women in the United 
States, 2% had subclinical hypothyroidism, 58% of whom had high anti-
TPO antibody values17. Smoking may worsen subclinical hypothyroidism 
and increase its peripheral effects. The effect of smoking was dose-
dependent. 
 
 
 
9 
 
NATURAL HISTORY 
         A substantial proportion of patients with subclinical hypothyroidism 
eventually develop overt hypothyroidism. In a follow-up of persons from 
the original Whickham Survey, women who had high serum TSH and 
antithyroid antibody concentrations developed hypothyroidism at a rate of 
4.3% yearly over 20 years, whereas women who had only high serum 
TSH concentrations or only high antibody concentrations developed 
hypothyroidism at an annual rate of 2.6% and 2.1%, respectively 4. In a 
New Mexico study of asymptomatic ambulatory subjects with subclinical 
hypothyroidism older than 60 years, one third developed overt 
hypothyroidism during 4 years of follow-up; among them were all those 
whose initial serum TSH concentrations were higher than 20 uIU/mL and 
80% of those whose serum anti-TPO antibody titers were 1:1600 or 
higher, but none with titers less than 1:1600. In an English study of 
persons with subclinical hypothyroidism followed for 1 year, 17.8% 
developed overt hypothyroidism, 5.5% had normal serum TSH 
concentrations, and 76.7% had persistent subclinical hypothyroidism15. 
The underlying cause of subclinical hypothyroidism also may predict 
progression to overt hypothyroidism. In one study, 53% of patients with 
subclinical hypothyroidism followed for 8 years became hypothyroid, and 
47% continued to have subclinical hypothyroidism. The former group 
included all patients with autoimmune thyroid disease, prior radioiodine 
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therapy, high-dose external radiotherapy, and long-term lithium therapy, 
whereas the latter group included patients with thyroid or neck surgery 
for indications other than hyperthyroidism or external neck radiotherapy 
during childhood18. 
 
BIOLOGIC IMPORTANCE 
The fundamental clinical question regarding patients with 
subclinical hypothyroidism is whether they require treatment with thyroid 
hormone. Based on the natural history of subclinical hypothyroidism 
alone, one can argue that treatment should be started to prevent the 
development of overt hypothyroidism. Additionally, goiter, if present, 
decreases in size in 77% of patients19. 
 
HYOPTHYROID SYMPTOMS AND PSYCOMETRIC 
OUTCOMES 
      Cooper et al. conducted double-blind trial in randomly assigned 
patients with subclinical hypothyroidism, including some patients with 
TSH >20 uIU/mL and symptoms such as dry skin, low energy and cold 
intolerance, to treatment with T4 or placebo for one year20. The dose of 
T4 was adjusted to normalize the serum TSH concentration. During 
treatment, one-half of the patients in the T4 group, but none in the 
placebo group, had fewer symptoms, as assessed by a standardized 
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hypothyroidism diagnostic index. Another trial was a double-blind cross-
over study by Nyström et al. in which patients received either T4 (0.15 
mg/day) or placebo, each for six months. The T4 dose was somewhat 
high; as a result, some patients may have had subclinical hyperthyroidism. 
Hypothyroid symptom scores and psychometric test results improved 
during the T4-treatment period, and about one-half of the patients felt 
better during this period, as compared with the placebo period21. 
 Jaeschke et al. in their 10-month double-blind trial found a 
significant improvement in psychometric test scores, but no improvement 
in quality of life, during treatment with T4; some TSH values were as 
high as 32 uIU/mL22. In three trials serum lipid concentrations improved, 
as did hypothyroid symptom scores . In another trial in 40 women, in 
whom TSH values were between 5 and 10 uIU/mL, T4 had no beneficial 
effect on metabolic, serum lipid, or quality of life measures as compared 
with placebo23. A double blind randomized treatment trial of 69 patients 
with serum TSH between 3.5 and 10 uIU/mL failed to show any 
difference in cognitive function, emotional function, or hypothyroid 
symptoms scores on 17 different standardized questionnaires24. Thus, in 
two of three trials, psychometric test scores improved, and in three of six 
trials, hypothyroid symptoms improved, but no benefit was seen in the 
two trials of patients whose TSH values were under 10 uIU/mL. 
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CARDIOVASCULAR EFFECTS 
Monzani et al. assessed only myocardial structure and contractility. 
Isovolumetric relaxation time and preejection/ejection ratio were 
increased and the cyclic variation index was decreased in patients with 
subclinical hypothyroidism. These alterations returned to normal with T4, 
but not with placebo. They also demonstrated an 11 percent improvement 
in carotid intima-media thickness with treatment of subclinical 
hypothyroidism25 .  
 
CARDIAC FUNCTION 
Diastolic blood pressure was unchanged in one study, increased in 
two studies and mean arterial pressure fell after T4 treatment in another 
study. Some patients with subclinical hypothyroidism have diastolic 
dysfunction and increased peripheral vascular resistance, as noted in 
patients with overt hypothyroidism, and cardiac output increases and 
systemic vascular resistance decreases after T4 treatment26,27,28. Right 
ventricular systolic and diastolic functions were abnormal in one study 
and improved with T4 treatment. Systolic time intervals usually do not 
change , unless they were initially prolonged. The left ventricular ejection 
fraction at rest or during moderate exercise does not change, but may 
increase during maximal exercise. Myocardial contractility during 
maximal exercise also may increase29.   
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CARDIOVASCULAR DISEASE 
Subclinical hypothyroidism may also be associated with an 
increased risk of cardiovascular disease, coronary heart disease, and 
possibly, all-cause mortality . This was illustrated by the following 
studies: Flow-mediated dilatation, a measure of vascular endothelial 
response and an early marker for atherosclerosis, was impaired in a cross-
sectional study of patients with subclinical hypothyroidism (mean TSH 
8.85) compared with matched euthyroid controls. 
The brachial-ankle pulse wave velocity, a parameter of arterial 
stiffening and a predictor of coronary atherosclerosis, was significantly 
increased in a cross-sectional study of patients with subclinical 
hypothyroidism (mean TSH 6.89). Central aortic pressure and arterial 
stiffness was increased in patients with subclinical hypothyroidism (mean 
TSH 8.8) and was reduced by treatment. Impaired endothelium-
dependent vasodilatation was reversed by thyroxine treatment in a fourth 
report.Serum C-reactive protein and plasma asymmetric dimethylarginine 
(an endogenous nitric oxide synthase inhibitor) concentrations, appear to 
be high in patients with subclinical hypothyroidism, and are normalized 
by levothyroxine administration30-33 . Platelet-activating factor (PAF) is a 
proinflammatory lipid mediator that has been implicated in atherogenesis. 
In plasma, PAF is inactivated by platelet-activating factor acetylhydrolase 
(PAF-AH). HDL-associated plasma PAF-AH activity is low in patients 
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with subclinical hypothyroidism (mean TSH 9.9), and increases to control 
values with levothyroxine therapy34. A number of observational studies 
have reported that, in general, older subjects with subclinical 
hypothyroidism are at increased risk for coronary heart disease. In one of 
these reports, the increased risk was seen in men, but not women , while 
in another, older subjects with subclinical hypothyroidism were at 
increased risk for developing heart failure, but not coronary heart 
disease(CHD)35. A meta-analysis of 14 observational studies of 
subclinical hypothyroidism calculated an overall increased risk of CHD 
(OR 1.65) . In summary, subclinical hypothyroidism may be associated 
with an increased risk of CHD. However, clinical trials are needed to 
assess whether thyroid hormone replacement reduces the risk of CHD in 
these patients. In contrast to the studies described above, the 
Cardiovascular Health Study of 3233 community-dwelling subjects over 
age 65 years reported that subclinical  hypothyroidism was not associated 
with an increased risk of CHD, adverse cardiovascular outcomes, or 
mortality36 . In addition, in a study of individuals over age 85 in the 
Netherlands followed for four years, those with untreated subclinical 
hypothyroidism actually had a lower rate of cardiovascular and all-cause 
mortality. 
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SERUM LIPIDS AND APOLIPOPROTEIN CONCENTRATIONS 
          Despite a few conflicting reports, many cross-sectional studies 
have found that serum total cholesterol concentrations in patients with 
subclinical hypothyroidism were similar to those of normal subjects; 
these concentrations did not consistently fall during T4 treatment. 
However, in the largest cross-sectional study to date (25,862 participants), 
subjects with modest elevations of serum TSH (between 5.1 and 10 
uIU/L) had significantly higher mean total cholesterol concentrations than 
those who were euthyroid (223 versus 216 mg/dL [5.6 versus 5.8 
mmol/L], p<0.03) 6. It is not known whether this difference is clinically 
important with regard to cardiovascular risk. 
         There are no consistent changes in serum low-density-lipoprotein 
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and 
apoprotein concentrations. In some studies patients with subclinical 
hypothyroidism had high serum LDL-cholesterol and low HDL- 
cholesterol concentrations37,38,39, but the values were normal in other 
studies41,42.  Serum apoprotein A1 concentrations were high in one study42 
and low in another41 , serum lipoprotein (a) concentrations were high in 
another study39, and serum apoprotein B concentrations were normal in 
some studies and high in two studies .In a randomized controlled trial in 
66 women with subclinical hypothyroidism treated with T4, serum total 
and LDL cholesterol, and apoprotein B-100 concentrations decreased 
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significantly, whereas serum HDL cholesterol, triglyceride, and 
lipoprotein (a) concentrations did not change43. In two other studies, only 
serum total and LDL cholesterol concentrations decreased after T4 
therapy. 
In another study, apoprotein B levels fell after T4 therapy41. And in 
two non-randomized trials serum lipoprotein (a) concentrations were 
reduced by T444. Further support for a mild increase in serum cholesterol 
in subclinical hypothyroidism comes from a pooled analysis of the 
published literature, which revealed that T4 therapy resulted in a small 
decrease in mean serum total cholesterol concentration of about 16 mg/dL 
(0.4mmol/L)45. In addition, a meta-analysis of 247 patients in 13 studies 
of subclinical hypothyroidism found that T4 therapy resulted in 
significant reductions in serum total cholesterol (8 mg/dL [0.2 mmol/L]) 
and serum LDL cholesterol (10 mg/dL [0.3 mmol/L]); the mean serum 
HDL cholesterol and triglyceride concentrations did not change. In this 
metaanalysis, reductions in serum cholesterol were only seen in patients 
with levels >240 mg/dL at baseline. Also, only those patients who had 
"subclinical hypothyroidism" based on inadequately treated overt 
hypothyroidism had statistically significant decreases in serum 
cholesterol46. 
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NEUROPSYCHIATRIC FEATURES 
         Reports of an increased prevalence of subclinical hypothyroidism 
in patients with depression or bipolar affective disorders need careful 
assessment because of frequently inadequate control groups, coincident 
lithium therapy, and the inclusion of patients with normal serum TSH 
values whose thyroid abnormality is limited to either an increased 
response of serum TSH to TRH administration or high serum antithyroid 
antibody concentrations47. Nonetheless, several studies suggest an 
association of subclinical hypothyroidism with neuropsychiatric 
abnormalities. In one study, the prevalence of hypothyroidism was 14.8% 
in patients with neurotic depression and 2.3% in those with senile and 
multiinfarct dementia, as compared with 1.9% in patients with no 
psychiatric disorder. Patients with depression and subclinical 
hypothyroidism had a higher prevalence of associated panic disorder and 
a poorer response to antidepressant drug therapy than depressed euthyroid 
patients48. Randomly selected women with subclinical hypothyroidism 
who had formal psychiatric assessment before assessment of thyroid 
function had a higher lifetime frequency of depression than euthyroid 
women49. Women found to have subclinical hypothyroidism after 
presenting to a clinic for assessment of goiter had increased rates of free-
flowing anxiety, somatic complaints, depressive features, and hysteria 
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compared with euthyroid women with goiter, and these abnormalities 
improved during treatment with T450.  
In DeFaZhu et al. study (2006), functional MRI (fMRI) )was used 
to measure brain functions by asking euthyroid subjects, hyperthyroid 
patients and subclinical hypothyroidism patients to perform the widely 
used digit n-back working memory task. After having been treated with 
L-thyroxine for 6 months, the subclinical hypothyroidism patients were 
asked to do the same fMRI experiment. The hypothyroid and subclinical 
hypothyroidism patients scored significantly lower in the 2-back task than 
either the hyperthyroid patients or the euthyroid subjects (P < 0.012). The 
fMRI showed that a common frontoparietal network, including bilateral 
middle/inferior frontal gyri (M/IFG), bilateral dorsolateral prefrontal 
cortex (DLPFC), bilateral premotor areas (PreMA), the supplementary 
motor area/anterior cingulate cortex (SMA/ACC) and bilateral parietal 
areas (PA), was activated by the n-back task in all the subjects. Further 
quantitative analysis showed that the load effect of blood oxygen level-
dependent (BOLD) response appeared in all the five regions of interest 
(ROIs) in the euthyroid and hyperthyroid subjects. In the pre-treatment 
subclinical hypothyroidism patients, however, the load effect of BOLD 
response was only found in the PA and PreMA, but not in other frontal 
cortex ROIs After an 6 month treatment with LT4, the subclinical 
hypothyroidism patients exhibited the same load effects in all five ROIs 
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as the euthyroid subjects along with an improvement of performance in n-
back task. These results suggest that working memory (but not other 
memory functions) is impaired in subclinical hypothyroidism patients. 
Both the memory performance and frontal executive functions were 
improved after an L-thyroxine-replacement treatment51. 
 
EFFECTS ON PREGNANCY AND FERTILITY 
Undetected subclinical hypothyroidism during pregnancy may 
adversely affect the neuropsychological development and survival of the 
fetus and be associated with hypertension and toxemia, screening of 
pregnant women has been advocated in many countries. During 
pregnancy, thyroid hormone needs rise 45 % because of increases in 
thyroid hormone binding globulin52. It is critical that euthyroidism be 
maintained throughout pregnancy as   shown by a recent study of women 
with a mean TSH level of only 13.2 uIU/mL at about 17 weeks of 
gestation. The offspring of these women had an average IQ score 4  
points lower than euthyroid controls at age 7 to 9 years (p=0.06).Of those 
women not treated at all with L-T4 during the pregnancy, their children had 
an IQ deficit of 7 points (P = . 005)53. In addition, data suggesting that 
subclinical hypothyroidism is associated with ovulatory dysfunction and 
infertility may make screening worthwhile in this population as well. 
Overt hypothyroidism may cause   infertility from anovulation and 
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menorrhagia from estrogen breakthrough bleeding. Pregnancies that do 
occur during overt hypothyroidism are at increased risk of abortion, 
stillbirths, and prematurity. Those with elevations of antithyroid 
peroxidase and antithyroglobulin antibodies have a 10% rate of 
spontaneous abortion (double that of normal controls).Subclinical 
hypothyroidism can also produce menorrhagia, anovulatory cycles, and 
luteal phase dysfunction, all of which can lead to infertility.54,55,56. A 
study of 127 women with adult-onset amenorrhea showed that 7.5 percent 
of participants had abnormal prolactin levels and 4.2 percent had 
abnormal TSH levels54 . 
Abalovich et al. showed that it was not so much the diagnosis of 
overt vs. subclinical hypothyroidism that mattered in relation with 
pregnancy outcome but mainly the adequacy of levothyroxine treatment. 
The outcome of pregnancy was compared in 27 women with 
hypothyroidism already known before pregnancy and who received an 
adequate levothyroxine treatment with 24 women in whom levothyroxine 
treatment was not adequately adjusted during gestation and who, hence, 
did not reach euthyroidism. When the treatment was not adequate, 
pregnancy ended with abortion in 60 and 71% of overt and subclinical 
hypothyroid women, respectively, with an increased prevalence of 
preterm deliveries. Conversely, in hypothyroid pregnant women who 
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received an adequate treatment, the frequency of abortions was minimal 
and pregnancies carried to term without complications57 . 
SERUM TSH ELEVATIONS NOT ASSOCIATED WITH 
SUBCLINICAL HYPOTHYROIDISM 
1. Recovery from nonthyroidal illness, at which time serum TSH 
may be transiently elevated for up to a week; these patients, 
therefore, should be reevaluated. Studies of subclinical 
hypothyroidism based on serum TSH measurements in 
hospitalized patients may be invalid because of failure to 
recognize this cause of high serum TSH values. 
2. An occasional serum TSH determination may exceed the normal 
reference range because of a robust pulse of TSH secretion, 
especially at night, or because of assay variability. 
3. Heterophilic antibodies, for example, in patients treated with 
monoclonal mouse antibody preparations, which interfere with 
TSH measurement. 
4. Adrenal insufficiency  
5. TSH-secreting pituitary adenomas, present as     thyrotoxicosis. 
6. Resistance to thyroid hormone; patient may be euthyroid  or 
possibly thyrotoxic. 
7. Metoclopramide or domperidone treatment 
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MANAGEMENT OF SUBCLINICAL HYPOTHYROIDISM 
Subclinical hypothyroidism is common, especially among older 
women. Treatment may be indicated to prevent progression to overt 
hypothyroidism, especially in patients who have serum TSH 
concentrations greater than 10 uIU/mL and high serum anti-TPO 
antibody concentrations58 . Progression to overt hypothyroidism occurs at 
a rate of 5 to 20 percent per year in patients with both mildly elevated 
TSH levels and antithyroid antibodies .Without treatment, only 5 percent 
of elevated serum thyrotropin levels will revert to normal values one year 
later in older persons. Treatment is also indicated if a goiter is present. 
The major immediate benefit of treatment is an improvement in 
symptoms and memory, a small reduction in serum total and LDL–
cholesterol concentrations, and possible improvement in cardiac 
contractility. 
Among patients with untreated subclinical hypothyroidism, there is 
no single level of serum TSH at which clinical action is always either 
indicated or contraindicated.As the TSH goes above 10 uIU/mL the basis 
for initiating treatment becomes more compelling .Clinical context is 
more important.There are no studies that demonstrate decreased mortality 
or morbidity with treatment.The potential risk of therapy are limited to 
the development of subclinical hyperthyroidism which may occur in 14 % 
to 15% cases.58 
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THOSE WITH TSH BETWEEN 4.5 AND 10 uIU/mL 
 
         Although early thyroxine treatment does not alter the natural 
history of disease it may prevent the symptoms and signs of overt disease 
in those who do progress.The available data do not confirm clear cut 
benefits for early therapy compared with treating when symptoms or 
overt hypothyroidism develops.There fore routine treatment of patients 
with TSH between 4.5 and 10 is not recommended, but thyroid function 
tests should be repeated at 6 to 12 months interval to monitor the 
improvement or worsening in TSH level.58 
Some individuals with TSH between 4.5 and 10 may have 
symptoms compatible with hypothyroidism.Here the clinician may decide 
on a several month trial of levothyroxine,while monitoring for 
improvement in hypothyroid symptoms.Continuation of therapy should 
be predicted on clear  symoptomatic benefit.58 
 
THOSE WITH TSH MORE THAN 10 uIU/mL 
In this group levothyroxine therapy is reasonable. Treatment may 
potentially prevent the manifestations and consequences of  
hypothyroidism in those patients who do progress. Still, the evidence that 
therapy will reduce the total and LDL cholesterol level and improve  
symptoms in these patients is inconclusive.58                                
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In general, treatment is strongly recommended in the following 
patients who have TSH levels higher than 10 uIU/L on repeated 
measurements, patients who have symptoms or signs (eg.goiter) 
associated with thyroid failure, patients who have convincing family 
history of thyroid disease, pregnant patients, patients who have a strong 
habit of tobacco use, or patients who have severe hyperlipidemia. An 
initial dose of thyroxine of 0.05 to 0.075 mg per day is usually sufficient 
to normalize the serum TSH level. Patients with coronary artery disease 
should receive lower initial doses (e.g., 0.0125 to 0.025 mg daily). Serum 
TSH levels should be measured four to six weeks after therapy is begun, 
after any change in the dose, and then annually, in order to achieve a 
serum TSH level between 0.5 and 3 mIU /mL once the levels become 
stable4,15.      
Arguments against treatment include the cost of therapy and the 
cost of monitoring therapy as well as the life-long commitment to daily 
medication in asymptomatic persons. In some patients, therapy may 
exacerbate angina pectoris or cardiac arrhythmia. If treatment is given, 
careful monitoring to avoid the adverse effects of subclinical 
thyrotoxicosis is mandatory. Although these concerns are not usually 
sufficient to counterbalance the benefits of therapy, recommendations are 
for a higher threshold for treating elderly patients with cardiovascular 
disease. If the patient is not treated, regular follow up is indicated. 
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AIMS AND OBJECTIVES 
 
1. To study the clinical profile of patients with subclinical 
hypothyroidism. 
2. To identify the causes of subclinical hypothyroidism. 
3. To identify the lipid profile abnormalities in patients with 
subclinical hypothyroidism. 
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MATERIALS AND METHODS 
Source of the data 
 
           This was a hospital based cross sectional study conducted in 
Government Rajaji Hospital, Madurai. All adult patients who fitted the 
biochemical criteria for subclinical hypothyroidism were included in the 
study. None of the patients were part of a routine screening programme. 
Design of study 
 
         Cross sectional, comparative study 
Period of study 
February 2008 to July 2008 
Sample size  
 Cases       44  
 Controls  40 
Ethical committee approval :obtained  
Consent : Informed consent obtained  
Financial support : Nil  
Conflict of interest : Nil  
Collaborating department: 
 
Department of Endocrinology 
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Selection of study subjects 
 
       Newly diagnosed cases of subclinical hypothyroidism patients who 
fulfilled the inclusion and exclusion criteria were included in the study. 
Inclusion criteria  
 
1.  All newly diagnosed cases of subclinical hypothyroidism(normal 
T3,T4&,fT4  with TSH more than 4.5uIU/mL)58 
Exclusion criteria 
1. Patients aged twelve or less. 
2. Patients already on thyroxine 
3. Patients who are not willing to give an informed consent. 
4. Chronic renal failure,Chronic liver disease 
5. Primary adrenal failure 
6. Severe non thyroidal illness. 
7. Patients who are on drugs like beta blockers,diuretics,steroids,OCP 
(causes dyslipidemia) and hypolipidemic drugs. 
8. Known cases of diabetes mellitus were excluded while comparing      
lipid profile. 
Selection of controls 
Controls were taken for comparing the lipid profile of the cases. 
Healthy euthyroid (normal T3,T4,TSH) population were taken as controls. 
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Exclusion criteria for controls 
1. Age less than 12 years. 
2. Diabetes mellitus 
3. Chronic renal failure 
4. Chronic liver disease 
5. Who were on drugs like beta blockers,diuretics,steroids,OCP & 
Lipid lowering drugs 
Method of study 
         The patients in the study were group evaluated with a detailed 
clinical history, thorough clinical examination and relevant laboratory 
investigations. The diagnosis of subclinical hypothyroidism was made 
according to the diagnostic criteria mentioned above. The evaluation 
aimed to look for the symptoms and signs, probable etiology & lipid 
abnormalities. 
Clinical data comprised of symptom analysis, thorough 
examination to identify signs, history of past medical illness and surgery, 
history of drug  intake and type of salt used. Laboratory data consisted of 
blood sugar, blood urea, serum creatinine,T3, T4 ,TSH ,Ft4,TPO antibody 
and fasting lipid profile. Blood urea, sugar and serum creatinine were 
estimated using ERBA XL300 automated analyzer.T3 and T4 was 
measured by Competitive Chemi Luminescent Immuno Assay and TSH 
by Ultra Sensitive Sandwich Chemi Luminescent Immuno Assay. Anti 
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TPOantibody estimation was done in all cases by 
electrochemiluminescence assay.A value more than 34 IU/L is taken as 
positive. Fasting lipid profile was done with the ERBA XL300 
autoanalyzer. Total cholesterol, Triglycerides and HDL were  estimated 
and LDL was calculated by the Friedwald’s equation : 
LDL Cholesterol = Total cholesterol - Triglycerides  - HDL-C.   
                 5 
 
Statistical Tools  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002).  
Using this software,  range, frequencies, percentages, means, 
standard deviations, chi square and  'p'  values were calculated. Kruskul 
Wallis chi-square  test was used to test the significance of difference 
between quantitative variables. A 'p' value less than 0.05 is taken to 
denote significant relationship. 
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RESULTS 
   
A. PROFILE OF STUDY CASES 
  
Table 1: AGE DISTRIBUTION 
  
 
 
Study cases 
Age in years No. % 
Upto 20 years 2 4.5 
21-30 7 15.9 
31-40 6 13.6 
41-50 20 45.5 
Above 50 9 20.5 
Total 44 100 
Range 
Mean 
S.D. 
13-68 
43.2 
11.8 
 
 
 
        A total of 44 newly diagnosed patients who fulfilled the inclusion  
criteria were studied.Their age ranged from 13 to 68 years and mean age 
was 43.2 years.Majority were in the age group 41 – 50 years. 
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Table - 2 
SEX DISTRIBUTION 
   
Study cases Sex 
No. % 
Male 3 6.8 
Female 41 93.2 
Total 44 100 
 
Out of the 44 cases 41 (93.2%) were females and only 3 ( 6.8%) 
were males. 
Table- 3 
B M I 
   
Study cases 
B M I No. % 
Lean     ( < 20) 10 22.7 
Normal (20-25) 30 68.2 
Obese   ( > 25) 4 9.1 
Total 44 100 
Range 
Mean 
S.D. 
20-26 
22.64 
1.6 
                    
 Majority of the cases were having BMI in the range 20 –25  
Kg/m2.(30 cases/68.2%). 
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Table - 4 
Symptoms 
 
   
Present Absent  
Symptoms No. % No. % 
Weight gain 26 59.1 18 40.9 
Tiredness 28 63.6 16 36.4 
Musculoskeletal 22 50 22 50 
Neck swelling 14 31.8 30 68.2 
Cold intolerance 17 38.6 27 61.4 
Constipation 16 36.4 28 63.6 
Voice changes 11 25 33 75 
Depression 2 4.5 42 95.5 
Infertility 3 6.8 41 93.2 
Menorrhagia 8 18.2 36 81.8 
Asymptomatic - - 44 100 
 
Most common symptom in our study was excessive tiredness, 
which was present in 28 cases(63.6%).Next to tiredness most common 
complaint was a recent gain in weight, present in 26 cases(59.1%). 
Musculoskeletal  complaints like myalgia and arthralgia was seen in 22 
cases(50%). Other symptoms were neck swelling, cold intolerance, 
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constipation, hoarse voice and menorrhagia. We had 3 cases referred 
from Obstetrics and  Gynaecology for evaluation of infertility and 2 cases 
from Psychiatry with clinical diagnosis of depression.None of our 
patients were entirely asymptomatic. Detaits of the symptoms are given 
in the table 4. 
 
Table - 5 
PAST HISTORY 
   
Present Absent  
Past Illness No. % No. % 
Hypertension 6 13.6 38 86.4 
DM 4 9.1 40 90.9 
IHD 4 9.1 40 90.9 
Thyroidectomy 2 4.5 42 95.5 
Hyperthyroidism      2    4.5    42   95.5 
 
Six of our cases had history of hypertension and was on treatment. 
Four cases were diabetic. All are having T2DM.We also had four patients 
with  Ischemic Heart Disease. Two cases had history of thyroidectomy 
for multinodular goiter. Two cases were on treatment for hyperthyroidism 
with  carbimazole. Details of past illnesses are depicted in the table 5. 
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Table - 6 
Salt Intake 
   
Study cases  
Salt Intake No. % 
Iodised salt 36 81.8 
Non iodised salt 8 18.2 
Total 44 100 
 
36 (81.8%) pateints in our study used to take iodised salt. Rest of 
the   cases used to take non-iodised salt. 
Table - 7 
DRUG HISTORY 
   
History of drug intake 
Yes No 
 
Drug 
No. % No. % 
Lithium - - 44 100 
Amiodorone 1 2.3 43 97.7 
Antithyroid drug 2 4.5 42 95.5 
Radio iodine - - 44 100 
Interferon - - 44 100 
 
             One patient with hypertension and ischemic heart disease was on  
Amiodarone for ventricular tachycardia for the past eight months. Two 
patients were on Carbimazole for hyperthyroidism. We didn’t have any 
patients on Lithium, Radio Iodine or Interferon. 
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Table - 8 
SIGNS ONCLINICAL EXAMINATION 
  
Study cases  
Parameter No. % 
Pulse 
Normal 
Bradycardia 
 
44 
- 
 
100 
- 
B.P. 
Normal 
Hypertension 
 
38 
6 
 
86.4 
13.6 
Goitre 
Yes 
No                           
 
24 
20 
 
54.5 
45.4 
Dry Skin 
Yes 
No 
 
18 
26 
 
40.9 
59.1 
Puffy Eyes 
Yes 
No 
 
9 
35 
 
20.5 
79.5 
Delayed 
relaxation of 
ankle jerk 
Yes 
No 
 
 
6 
38 
 
 
13.6 
86.4 
 
   Most common sign was presence of goiter, which was  seen in 24 
cases(54.5%).Other signs were dry skin and puffiness of face and  eyes 
present in 18(40.9%) and 9(20.5%) cases respectively.A delayed 
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relaxation of ankle jerk was present only in 6(13.6%) cases.None had  
bradycardia. 
Table - 9 
TSH DISTRIBUTION 
 
TSH(uIU/mL)        No          % 
     < 10       8        18.2 
    10 - 20       33         75 
      > 20        3         6.8 
 
33 cases (75%) were having TSH in the range 10 to 20. 8 
patients(18.2%)had TSH between 5 and 10.Only 3 cases(6.8%) were 
having TSH above 20. 
Table - 10 
THYROID PEROXIDASE ANTIBODY(TPO Ab) 
                
 TPO Ab        No       % 
 Positive(>34IU/L)        26     56.1 
 Negative       18     40.9 
 
             
        26 cases (56.1%) had positive thyroid peroxidase antibody while 
18 (40.9%) were negative for TPO Ab. 
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Table - 11 
ETIOLOGY OF SUBCLINICAL HYOPOTHYROIDISM  
IN OUR STUDY. 
              
         ETIOLOGY No % 
Auto immune thyroiditis     26   56.1 
Post thyroidectomy      2     4.5 
Antithyroid drugs       2    4.5 
Amiodarone      1    2.3 
Others     13   29.5 
 
Most common cause of subclinical hypothyroidism in our study 
was Autoimmune thyroiditis,as suggested by the presence of thyroid 
peroxidase antibody,seen in 26 cases(56.1%).Other causes were post  
thyroidectomy and drug induced like antithyroid agent Carbimazole and 
antiarrythmic Amiodarone.No definite cause were found in 13 cases 
(2.5%). Details are depicted in table 11. 
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COMPARISON OF STUDY CASES AND CONTROL CASES 
 
Table - 12 
Age 
   
Study cases Control cases  
Age group No. % No. % 
Upto 20 years 2 4.5 2 5 
21-30 7 15.9 5 12.5 
31-40 6 13.6 5 12.5 
41-50 20 45.5 16 40 
Above 50 9 20.5 12 30 
Total 44 100 40 100 
Range 
Mean 
S.D. 
13-68 
43.2 
11.8 
15-63 
44.8 
12.2 
‘p’ 0.3697 
Not Significant 
 
There was no significant difference in age distribution between the  
 
cases and the control group and hence they were comparable. 
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Table - 13 
Sex 
 
   
Study cases Control cases  
Sex No. % No. % 
Male 3 6.8 - 0 
Female 41 93.2 40 100 
‘p’ 0.8524 
Not Significant 
 
There was no significant difference in sex distribution between the 
cases and the control group and hence they were comparable 
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Table - 14 
BMI 
   
Study cases Control cases  
BMI No. % No. % 
Lean ( Upto 20) 10 22.7 14 35 
Non Obese (20.1-25) 30 68.2 24 60 
Obese ( > 25) 4 9.1 2 5 
Total 44 100 40 100 
Range 
Mean 
S.D. 
20-26 
22.64 
1.6 
19-27 
22.01 
1.63 
‘p’ 0.0693 
Not Significant 
 
 
There was no significant difference in BMI between the cases and 
the control group and hence they were comparable. 
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C : COMPARISON OF LIPID PROFILE 
( *Only for case with normal fasting blood sugar) 
 
Table - 15 
Total Cholesterol 
   
Study cases 
(Subclinical 
hypothyroidism)
Control cases 
(Euthyroid) 
 
Total Cholesterol 
No. % No. % 
Normal (< 200) 16 40 38 95 
Borderline (201-239) 8 20 2 5 
High ( > 240) 16 40 - - 
Total 40* 100 40 100 
Range 
Mean 
S.D. 
107-335 
213.3 
59.6 
132-220 
165.8 
19.4 
‘p’ 0.0001 
Significant 
 
Hypercholesterolemia was present in 60% of subclinical  
hypothyroidism  patients. The mean total cholesterol was 213.3 mg/dl in 
study cases and  165.8 mg/dl in control population. The difference was 
statistically significant . (p value 0.0001). 
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Table - 16 
L D L 
   
Study cases Control cases  
L D L No. % No. % 
Normal (< 130) 19 47.5 38 95 
Borderline (131-159) 2 5 2 5 
High ( > 160) 19 47.5 - - 
Total 40 100 40 100 
Range 
Mean 
S.D. 
49-238 
138.6 
48.7 
74-150 
109.4 
18.1 
‘p’ 0.005 
Significant 
 
 
LDL was elevated in 52.5% of subclinical hypothyroid group. 
47.5% of cases had LDL more than 160mg/dl.The mean LDL in study 
cases was 138.6 mg/dl and 109.4 mg/dl in control group. The difference 
was  statistically significant.(p value 0.005).  
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Table - 17 
T G L 
   
Study cases Control cases  
T G L No. % No. % 
Normal (< 150) 29 72.5 38 95 
Borderline  (151-199) 6 15 1 2.5 
High ( > 200) 5 12.5 1 2.5 
Total 40 100 40 100 
Range 
Mean 
S.D. 
63-435 
143.6 
81.1 
93-224 
126.4 
23.7 
‘p’ 0.4853 
Not Significant 
 
 
72.5% of the study cases were having triglycerides less than 150 
mg/dl. The mean triglyceride level in subclinical hypothyroid group was 
143.6 mg/dl and 126.4 mg/dl in control group. The difference was not 
statistically significant.(p value 0.4853). 
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Table - 18 
HDL 
   
Study cases Control cases  
HDL No. % No. % 
Normal ( > 40) 27 67.5 30 75 
Low( < 40) 13 32.5 10 25 
Total 40 100 40 100 
Range 
Mean 
S.D. 
26-80 
46.08 
13.77 
30-71 
49.93 
11.37 
‘p’ 0.0813 
Not Significant 
 
 
Majority of the study cases (67.5%) and control ( 75%) had HDL 
with  in normal range. The mean HDL was 46.08 mg/dl in study group 
and 49.93 mg/dl in control group.The difference was not significant 
statistically.( p value 0.0813). 
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DISCUSSION 
 
           Subclinical hypothyroidism is defined as an elevated serum TSH 
with normal free T4. It is a more common condition than overt 
hypothyroidism. Many studies have shown that patients with subclinical  
hypothyroidism are not entirely asymptomatic, rather they do have many 
of  the symptoms and signs of overt hypoythyroidism. In fact the term 
mild hypothyroidism or mild thyroid failure will be a more apt 
terminology for this condition 2.This study was done to find out the 
symptoms and signs, probable etiologies and lipid abnormalities in 
patients with subclinical hypoythyroidism, who presented in Government 
Rajaji Hospital,  Madurai. 
Among the 44 patients studied, the mean age was 43.2 years, range  
being 13 to 68 years. Majority of the patients (66%) were in the age 
group  41 – 68 years. Studies have shown that the incidence of subclinical 
hypothyroidism increases with age. The Colorado Thyroid Disease 
Prevalence Study had clearly demonstrated the increase in serum TSH  
with age 6( Fig 12). We had only 9 patients (20.5%) above the age group 
50 years. This difference maybe due to the fact that those studies were 
community based screening studies done on large population. So 
screening in elderly population may be needed to detect more cases as 
larger studies have shown that majority of the patients are asymptomatic. 
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Fig 12 
                               
 
  
  
  
 
 
 
 
 
 
 
 
 
    Studies have proven that the incidence of subclinical 
hypothyroidism is more in females. In our study also majority were 
females (93.2%). In a study on dyslipidemia in subclinical 
hypothyroidism by Bandyopadhay and co workers they also reported that 
78% of their cases were females59. 
 
SYMPTOMS AND SIGNS OF SUBCLINICAL 
HYPOTHYROIDISM 
Our study revealed that patients with subclinical hypothyroidism 
have symptoms that closely resemble that of overt hypothyroidism. 
Almost all patients had one or more symptoms mentioned in table 4. 
None of our cases were totally asymptomatic. This maybe due to the fact 
that ours is a hospital based study and we tend to miss those who are 
entirely asymptomatic unless screening has been done in high risk 
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population.Most common symptom was excessive tiredness (63.6%) 
followed by weight gain (59.1%) and musculoskeletal symptoms like 
myalgia and arthralgia (50%). Other symptoms noticed were neck 
swelling, constipation, cold intolerance, voice changes, depression, 
infertility and menorrhagia. The Colorado Thyroid Prevalence Study also 
revealed that subclinical hypothyroidism have symptoms similar to 
hypothyroidism. In their study 2,336 subjects who were identified as 
having mild thyroid failure, significantly reported more often having dry 
skin (28%; P < 0.001), poor memory (24%; P < 0.001), slow  thinking 
(22%; P < 0.001), muscle weakness (22%; P < 0.001), fatigue 18%; P < 
0.01), muscle cramps (17%; P < 0.001), cold intolerance (15%; P < 
0.001), puffy eyes (12%; P < 0.05), constipation (8%;P < 0.05), and  
hoarseness (7%; P < 0.05) than did euthyroid subjects. It is important to 
note that, where as euthyroid subjects experienced a mean of 12.1% of all 
listed symptoms, overtly hypothyroid subjects had 16.6% of these 
symptoms (P < 0.05 vs. euthyroid group), and subjects with mild thyroid 
failure reported an intermediate 13.7% of the symptoms (P < 0.05 vs. 
euthyroid group). (Fig. 13). This suggests a "dosage effect" between 
levels of thyroid hormones and symptoms. 6 
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 Fig 13.  The Colorado Thyroid Disease Prevalence Study 
 
In a study on clinico biochemical spectrum of hypothyroidism by 
Sampath et al generalized weakness and weight gain were the most 
common symptoms reported by both subclinical hypothyroid patients and 
overt hypothyroid patients60. 
Most common sign in our study was presence of goiter. Other signs 
were dry skin, puffiness of eyes and delayed relaxation of ankle jerk 
(table 8). 
Except for goiter, signs in our study were similar to the 
observations in the Colorado study and the work by Sampath et al. It may 
be noted that goiter has been shown by other studies to be twice as 
prevalent among patients with subclinical hypothyroidism as in the 
general population61.  
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In our study we had two patients with depression referred from  
psychiatry department. Neither of them were on any drugs. In a study by 
Haggerty et al the lifetime frequency of depression was significantly 
higher in the subjects who met the criteria for subclinical hypothyroidism 
(56%), than in those who did not (20%), suggesting that subclinical 
hypothyroidism may lower the threshold for the occurrence of 
depression49. In another study by Sampath et al 109 patients with 
depression were tested for thyroid dysfunction. 42.2% of them had 
subclinical hypothyroidism and 3.6% had overt hypothyroidism60. So all 
patients with depression should have a thyroid function test. 
The prevalence of subclinical hypothyroidism has been reported to 
be 0.7–2.3% in a large series of unselected infertile women by Shalev et 
al 1994 & Lincoln et al 199962,63. In our study 6.8% cases were having 
primary infertility. Some patients with infertility and menstrual 
irregularities may have underlying chronic thyroiditis in conjunction with 
subclinical or clinical hypothyroidism. Typically these patients seek 
medical attention because of infertility or a previous miscarriage, rather 
than hypothyroidism64. In the study by Sampath et al among 105 patients 
with primary infertility three patients were hypothyroid and 39 (37.1%) 
patients had subclinical hypothyroidism (total of 40% had thyroid  
dysfunction in the form of subclinical or overt hypothyroidism)60.  
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SUBCLINICAL HYPOTHYROIDISM AND IODINE INTAKE 
Another important observation of our study was significant 
incidence of goiter  and  subclinical hypothyroidism in a population 
where majority were on  iodised salts (81.8% of total study group) .  
Iodine is essential for thyroid function. Thyroid disorders related to 
iodine deficiency have decreased progressively with iodine prophylaxis 
and the increased overall iodine intake.  
Acute excess iodine ingestion has long been known to result in a 
transient decrease in iodine organification, termed the acute Wolff- 
Chaikoff effect .With sustained excess iodine exposure, however, most 
individuals’ thyroid glands escape from this acute Wolff-Chaikoff effect 
despite the exposure and resume synthesis of normal amounts of T4 and 
T3. The mechanism responsible for this escape or adaptation to the iodine 
load probably involves a decrease in the Na+/I-  symporter protein, 
resulting in a decrease in thyroid iodide content .In some individuals this 
escape phenomenon does not occur, and those patients develop iodine-
induced hypothyroidism. Such hypothyroidism generally is reversible 
when the source of excess iodine exposure is removed.  
Another adverse effect resulting from iodine prophylaxis may be 
the induction of thyroid autoimmunity. Iodine and iodine containing 
drugs can precipitate autoimmune thyroiditis in susceptible populations65. 
Most common cause of subclinical hypothyroidism in our study was also 
52 
 
autoimmune thyroiditis as suggested by TPO antibodies.(table 11). A 
cross-sectional survey of 102 Peace Corps volunteers in Niger, West 
Africa, in 1998  had demonstrated a high rate of thyroid dysfunction and 
goiter attributable to excess iodine from their water filters. The study 
showed that during prolonged excess iodine exposure, there was a marked 
increase in serum total iodine concentrations. And the prevalence of 
goiter, elevated serum TSH values, and elevated serum thyroid peroxidase 
antibody values also increased. The prevalence of all abnormalities 
decreased after removal of excess iodine from the drinking water system66. 
Thyroid autoimmune diseases are complex, polygenic afflictions, the 
penetrance of which is heavily dependent on various environmental 
influences. In general, iodine deficiency attenuates, while iodine excess 
accelerates autoimmune thyroiditis in autoimmune prone individuals67 .  
In the present scenario of the post–iodination status in India, the 
high prevalence of subclinical hypothyroidism is significant as similar 
findings were reported from other countries, stating subclinical 
hypothyroidism is more prevalent and marked in subjects consuming 
excessive amounts of iodine. Excessive iodine intake should be 
considered an etiology of subclinical hypothyroidism in addition to 
chronic thyroiditis in these areas. 
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ETIOLOGY 
        Our study evaluated the causes for subclinical hypothyroidism. 
Most important aetiology found was autoimmune thyroiditis. Other 
causes were post thyroidectomy and drug induced like antithyroid agent 
Carbimazole and antiarrythmic like Amiodarone. No definite cause was 
found in 13 cases (29.5%).  
Autoimmune thyroidits was diagnosed by doing anti TPO assay. 
56.1% patients had positive thyroid peroxidase antibody test. This result 
was similar to the study by Shruti Mohanty and team where 45 out of 61 
subclinical hypothyroid cases had TPO antibodies suggesting 
autoimmune thyroiditis as the cause68. Published literature states that the 
most common cause of subclinical hypothyroidism is autoimmune 
thyroiditis (Hashimoto’s disease)64. Progression to overt hypothyroidism 
is reported to vary from 3 to 20%, the risks being greater in those patients 
with  TSH more than 10 uIU/mL or thyroid antibodies (or both). Hence it 
is recommended that anti- TPO measurement should be an integral part of 
the investigation in subclinical hypothyroidism.  
In a study by  Ian Louis Ross about thyroid dysfunction in patients 
on amiodarone, he found that hypothyroidism was the common 
abnormality and subclinical hypothyroidism was present in 13% of 
cases69. Some studies indicate that the incidence of thyroid dysfunction 
with amiodarone varies with the dietary iodine intake in the population. 
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Amiodarone Induced Thyrotoxicosis occurs more frequently in 
geographical areas with low iodine intake, whereas Amiodarone Induced 
Hypothyroidism is more frequent in iodine-replete areas. Our study 
population was from  an iodine-replete area and amiodarone was indeed 
found to be a cause for subclinical hypothyroidism. 
SUBCLINICAL HYPOTHYROIDISM AND DYSLIPIDEMIA 
While the association between overt hypothyroidism and alteration 
in lipid profile is an undisputed fact, the situation is less clear when 
subclinical hypothyroidism is concerned. The relationship between 
subclinical hypothyroidism and reversibly elevated lipid levels has been 
widely investigated, but the results remain highly controversial. 
In this study, there was found to be a significant increase in the 
total cholesterol and  LDL levels in study cases when compared with 
euthyroid controls, but the variation in HDL and triglycerides were not 
significant.  
This result was similar to the observations made in The Colorado 
Thyroid Prevalence Study where they found statistically significant 
elevation in total cholesterol and LDL in subclinical hypothyroid cases 
compared with euthyroid controls6. Another study done in India by 
Guptha and Sinha also demonstrated a significant elevation in serum 
cholesterol in subclinical hypothyroid cases when compared with 
euthyroid controls70. Same results were obtained in the study by       
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Walsh J P & colleagues71. A recent meta-analysis of the effect of 
treatment with thyroxine on lipid profile  in mild thyroid failure cases by 
Mark D. Danese and colleagues has demonstrated a mean reduction in the 
total cholesterol level of 7.9 mg per deciliter (0.2 mmol per liter) and in 
the LDL cholesterol level of 10 mg per deciliter (0.26 mmol per liter). 
Changes in high-density lipoprotein (HDL) cholesterol were 
heterogeneous among the studies and were not statistically significant46. 
 A cross sectional study on the lipid abnormalities in subclinical 
hypothyroidism by Z Efstathiadou and coworkers demonstrated 
significant elevation of total cholesterol,LDL-C,apolipoprotein B and 
Lp(a) in subclinical hypothyroidism patients compared with euthyroid (p 
value<0.05).They also demonstrated that changes in triglycerides and 
HDL-C was not significant72.These results were similar to our study.In 
conclusion lipid abnormalities are relatively common in subclinical 
hypothyroidism.Several randomized controled trials have shown that 
treatment of subclinical hypothyroidism with thyroxine may have a 
favourable effect on the lipid profile by decreasing total cholesterol and 
LDL-C.  
These observations reinforces the need to screen for thyroid 
dysfunction in people with dyslipidemia, as this may be a reversible cause, 
amenable to thyroxine  replacement.  
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72.7% of our patients (32/44) had indications as per the current 
recommendations for initiating thyroxine therapy. Indications for 
thyroxine were TSH more than 10 uIU/mL, TPO antibody positivity, 
presence of goiter, elevated total cholesterol or LDL and infertility. 
Majority had more than one indication as per the recommendations. 
Therapy was initiated with 50 mcg of thyroxine once daily. Untreated 
patients were adviced repeat thyroid function test after six months. 
Treated patients were also advised long term follow up to assess the 
benefit of therapy as well as to prevent therapy related complications like 
devolopment of iatrogenic hyperthyroidism. 
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CONCLUSIONS 
 
1. Incidence  of  subclinical hypothyroidism is more in females as  
expected. 
2. Being a hospital based study almost all of our patients are 
symptomatic.We tend to miss those who are entirely asymptomatic. 
Screening programmes in high risk population may help to detect 
those cases.  
3. Most common symptom is excessive tiredness and most common 
sign is goiter. 
4. Majority of our patients are at high risk for progressing to overt 
hypothyroidism (TSH>10 uIU/mL & TPO positivity).  
5. 75% of  patients has TSH between 10 and 20 uIU/mL. 
6. TPO antibody is positive in 56.1% of cases. 
7. Auto immune thyroiditis is the most common cause of subclinical 
hypothyroidism in our study. 
8. Occurence of goiter and autoimmune thyroiditis in an iodine 
sufficient population supports the hypothesis that iodine may 
initiate or exacerbate thyroid autoimmunity in susceptible persons. 
9. Subclinical hypothyroidism may be associated with infertility and  
depression. Screening may be beneficial in such cases. 
10. Lipid abnormalities are seen in subclinical hypothyroidism patients 
in the form of significant elevation of total cholesterol and LDL 
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while changes in HDL and triglycerides are not significant. Follow 
up of treated patients are necessary to assess the benefit of 
thyoxine in  reverting the lipid abnormalities. 
11. 72.7% of cases received treatment with thyroxine in our study. 
Majority of them has multiple indications for starting treatment as 
per the current recommendations like TSH more than 10 uIU/mL, 
TPO Antibody positivity, goiter, hypothyroid symptoms, 
dyslipidemia and infertility. Follow up is needed to assess the 
benefit of treatment. 
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SUMMARY 
 
Subclinical hypothyroidism is defined as an elevated serum TSH 
level associated with normal total or free T4 and T3 levels. This is a 
much more common disorder than overt hypothyroidism. 
This study was done to find out the symptoms and signs, probable 
etiologies and lipid abnormalities in patients with subclinical 
hypoythyroidism, who presented in Government Rajaji Hospital, Madurai. 
After institutional ethical clearance, with an informed consent and 
with inclusion and exclusion criteria 44 cases of subclinical 
hypothyroidism were included in the study and were evaluated on clinical 
and biochemical aspects. For comparing the lipid profile, 40 euthyroid 
controls who were age, sex and  BMI  matched and fitted the inclusion 
and exclusion criteria were selected. The data was entered in the master 
sheet and  analysed statistically. 
Subclinical hypothyroidism was more common in females in our 
study. Being a hospital based study majority of our patients were having 
symptoms.We tend to miss those patients who are entirely asymptomatic. 
Screening of high risk populations may help to detect those cases.  The 
most common symptom was excessive tiredness, weight gain and 
musculoskeletal complaints like myalgia and arthralgia. Goiter was the 
most common sign on physical  examination. Most of our patients were 
having risk factors for progression to overt hypothyroidism like baseline 
60 
 
TSH > 10 uIU/mL and presence of TPO antibodies. Auto immune 
thyroiditis was identified as the most common cause of subclinical 
hypothyroidism in our study. Diagnosis was made by the presence of 
TPO antibodies. The observation of increased incidence of autoimmune 
thyroiditis in an iodine sufficient population is supporting the hypothesis 
that thyroid autoimmunity can be initiated by iodine in susceptible 
individuals. Depression and infertility may be associated with subclinical 
hypothyroidism and screening of such individuals may be useful. 
Compared with euthyroid controls, cases with subclinical hypothyroidism 
had significantly elevated total cholesterol and LDL-C levels. Majority of 
our patients had multiple indications for starting thyroxine as per the 
current recommendations. 
It is very important to follow up the treated cases for assessing the 
benefit of thyroxine on different aspects of subclinical hypothyroidism 
namely the effect on symptoms, reduction in goiter size, improvement in 
lipid abnormalities and also to avoid over treatment as .  Untreated cases 
has to be followed up for evidence of progression of disease. 
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APPENDIX I 
PROFORMA 
STUDY ON CLINICAL PROFILE AND LIPID ABNORMALITIES 
IN SUBCLINICAL HYPOTHYROIDISM 
Name                                                           Age                   Sex 
Address                                                       Occupation 
Phone                                                          
FINAL DIAGNOSIS 
 
DIAGNOSTIC CRITERIA 
Elevated TSH level(>4.5uIU/mL) with normal total or free T4 & T3 
values 
SYMPTOMS 
Asymptomatic                             Tiredness  
Weightgain                                  Neck swelling                                                 
Muscle weakness                        Depression                                                                     
Muscle cramps                             Cold intolerance                      
Myalgia,arthralhia                        Anorexia    
Constipation                                 Infertility  
 
 
 
  PAST HISTORY 
 CAD                        Dyslipidemia                     DM                       
 Hypertension           Autoimmune diseases       CRF 
 TB               Thyroidectomy                     Asthma    
Severe nonthyroidal Illness   Adrenal Failure 
Menstrual History:        Menorrhagia           Menopause                       
Obstetric History :         Infertility,miscarriages            
Treatment history: H/o:Drugs (Thyroxin / Lithium /             
Amiadarone,antithyroid,Interferon),Radio iodine  ,H/o neck Radiation . 
Salt intake  :   Iodised / non iodised  
GENERAL EXAMINATION 
Built     Nourishment                         BMI              Pallor 
Icterus             Cyanosis        Clubbing        Edema       Lymphadenopathy 
Pulse rate         BP                 RR                  Temp            Peripheral pulses 
THYROID 
Diffuse                           Nodular                Thyroidectomy scar 
RESPIRATORY SYSTEM 
 Pleural Effusion                Other findings   
 
CVS 
Cardiomegaly                      Murmur 
 
MUSCULO SKELETAL 
Arthralgia- 
Myalgia 
Stiffness                   Carpel tunnel syndrome             Muscle weakness 
NERVOUS SYSTEM   
Neuropathy                           Seizures          
Cerebellar signs                    Delayed Relaxation of DTR     
ALIMENTARY SYSTEM 
OTHERS  
Periorbital Puffiness              Dry, Coarse Skin                   Ichthyosis 
Macroglossia                    Loss of Hair 
INVESTIGATIONS 
Urine -  Albumin        , Sugar          , Casts          , RBC            
FBS,  PPBS,  Blood Urea    , Serum Creatinine 
TFT-             T3                T4,fT4               TSH 
FLP-              T. CHOLESTEROL            LDL                 HDL          TG 
Immunological test  
Anti TPO Antibodies             
 
 
 
 
 
 
 
 
APPENDIX II 
MASTER CHART CASES 
Sl 
No age sex wt.gain tiredness 
musculosk
eletal 
neck 
swelling 
cold 
intolerance constipation 
1 39 1 2 1 1 2 1 2 
2 26 1 1 1 1 1 2 2 
3 44 1 1 1 2 2 2 2 
1 13 1 2 2 1 1 2 2 
5 50 1 1 2 2 2 1 2 
6 28 1 1 2 1 1 1 2 
7 48 1 1 1 2 2 2 1 
8 47 1 1 1 2 2 2 1 
9 53 1 2 1 2 2 2 1 
10 33 1 1 2 1 1 1 2 
11 50 1 1 1 2 2 1 2 
12 54 1 1 1 2 2 1 2 
13 22 1 1 2 2 1 2 2 
14 42 1 2 1 2 2 1 1 
15 45 1 1 1 2 2 2 2 
2 52 1 1 1 1 2 2 2 
17 50 1 2 2 1 2 2 1 
18 39 1 1 1 2 1 2 1 
19 58 1 2 2 1 2 2 1 
20 49 1 1 2 2 1 1 2 
21 44 1 1 1 1 2 2 2 
22 38 1 1 1 2 2 1 1 
23 30 1 2 1 1 1 1 2 
24 48 1 2 1 1 2 2 2 
25 39 1 1 2 2 2 1 2 
26 46 1 2 1 1 2 2 1 
27 49 1 2 1 2 2 2 1 
28 34 1 2 1 1 1 1 2 
29 49 2 1 1 2 2 2 2 
30 55 1 1 2 1 2 2 2 
31 44 1 2 2 2 2 1 2 
32 24 1 1 1 1 1 2 2 
33 68 2 2 1 1 1 2 1 
34 58 1 2 2 1 2 1 2 
35 47 1 2 2 1 2 1 2 
36 60 1 2 2 1 2 2 1 
37 54 1 1 1 2 2 2 1 
38 49 2 2 1 1 2 2 2 
39 20 1 1 2 2 1 2 1 
40 48 1 1 1 2 2 1 2 
41 50 1 2 2 1 2 1 1 
42 30 1 1 1 2 2 2 2 
43 28 1 1 1 2 1 2 1 
44 45 1 1 1 1 1 2 2 
 
 
 
voice 
change 
depress
ion infertility menorrhagia asymptomatic 
salt 
intake 
Hyper 
tension DM IHD 
2 2 2 2 2 1 2 2 2 
2 2 2 1 2 1 2 2 2 
1 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 1 2 1 2 2 2 
1 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 1 1 2 2 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 1 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
1 2 2 2 2 1 2 2 2 
2 2 2 2 2 2 2 2 2 
1 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 1 2 2 
2 2 2 2 2 1 2 2 2 
1 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 1 1 2 2 2 2 2 
2 2 2 2 2 2 2 2 2 
2 1 2 2 2 1 2 2 2 
1 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 1 2 2 1 2 2 2 
1 2 2 2 2 2 1 1 2 
2 2 2 2 2 2 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
2 2 2 2 2 1 1 1 1 
2 2 2 2 2 1 1 1 1 
2 2 2 2 2 2 2 2 2 
2 2 2 2 2 1 1 2 1 
1 2 2 2 2 1 2 2 2 
1 2 2 2 2 1 1 1 1 
2 2 2 1 2 1 2 2 2 
1 1 2 2 2 2 2 2 2 
2 2 2 2 2 1 2 2 2 
1 2 2 1 2 1 2 2 2 
2 2 2 1 2 1 2 2 2 
2 2 2 2 2 1 2 2 2 
 
 
 
 
 
 
Hyper 
thyroidism 
Thyroid 
dectomy Lithium Amiodarone
Antithyroid 
drugs RAI Interferon pulse BP 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
1 2 2 2 1 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 1 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
1 2 2 2 1 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 2 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 1 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 2 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 1 2 2 2 1 2 
2 2 2 2 2 2 2 1 2 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 2 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 2 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
2 2 2 2 2 2 2 1 1 
 
 
 
 
 goitre 
dry 
skin 
puffy 
eyes DRAJ BMI FBS TSH FT4 
TPO 
Ab TC TG LDL HDL
LT4 
STARTED
2 1 2 2 20 1 24.6 1.23 1 185 100 120 45 1 
1 2 1 2 22 1 17.7 2.2 1 260 185 180 43 1 
1 1 2 2 21 1 14.73 1.4 1 255 90 191 46 1 
1 2 2 2 20 1 14.07 1.9 2 156 80 102 38 1 
2 1 1 2 25 1 7.19 0.98 2 120 66 67 40 2 
1 1 2 1 22 1 16.6 1.3 1 113 92 49 46 1 
2 1 2 2 22 1 18.76 1.76 1 233 122 167 42 1 
1 2 1 2 23 1 6.98 2 2 146 78 98 32 2 
2 2 2 2 21 1 8.7 2.4 2 180 142 106 46 2 
1 2 2 2 22 1 14 2.3 1 310 119 238 48 1 
2 1 2 1 23 1 7.8 1.7 2 107 72 56 37 2 
2 1 2 1 24 1 10.2 1.5 2 126 98 80 26 2 
1 2 2 2 23 1 19.8 1.32 1 137 63 90 35 1 
2 1 2 2 25 1 13.2 2.23 1 262 284 149 56 1 
2 2 2 2 22 1 14.3 1.65 2 160 110 101 37 1 
2 1 1 2 21 1 10.8 1.4 1 280 122 208 48 1 
2 2 2 2 23 1 7.6 1.6 2 204 106 127 56 2 
1 2 2 2 21 1 12.9 1.73 1 241 96 188 34 1 
2 2 2 2 26 1 10 0.93 2 222 92 154 50 2 
1 1 2 2 23 1 11.5 1.65 1 246 82 189 41 1 
1 2 2 2 22 1 13.6 1.8 1 246 435 131 28 1 
2 2 2 2 23 1 14.7 1.32 2 117 128 61 30 1 
1 2 2 1 21 1 15.8 1.97 1 184 94 122 43 1 
1 1 1 2 22 1 10.1 1.08 2 138 109 85 31 2 
2 2 2 2 26 1 13.7 1.5 2 302 112 227 56 1 
1 1 2 1 22 1 10.4 2.03 1 196 272 103 39 1 
2 2 1 2 23 1 14.2 1.04 1 253 83 81 56 1 
1 2 2 2 20 1 16.6 1.23 1 226 136 164 62 1 
2 1 1 2 22 2 7.22 1.09 2 230 149 148 52 2 
1 2 2 2 23 1 15.9 2.2 2 238 112 178 68 1 
2 1 2 2 22 1 10 1.8 2 246 187 170 40 2 
1 2 2 2 21 1 17.5 1.43 1 242 126 186 72 1 
1 2 2 2 24 2 7.73 1.06 2 262 164 188 66 2 
1 1 2 2 23 2 8.86 1.97 2 266 132 152 52 2 
1 2 2 2 24 1 17.7 2.3 1 276 186 178 61 1 
1 2 2 2 26 1 14.87 1.3 1 294 163 181 80 1 
2 2 2 1 23 1 16.6 1.68 1 180 149 104 46 1 
2 1 2 2 22 2 11.2 2.53 1 256 207 172 42 1 
1 2 2 2 24 1 1O.3 0.99 1 271 232 158 66 1 
2 2 2 2 26 1 18.9 1.07 2 335 385 180 78 1 
1 2 1 2 23 1 21.8 2.23 1 198 190 129 31 1 
2 1 2 2 21 1 12.8 2.65 1 221 144 162 30 1 
1 2 2 2 22 1 22.7 1.9 1 218 113 164 32 1 
1 1 1 2 22 1 15.8 2.43 1 206 187 120 48 1 
 
 
 
 
MASTER CHART CONTROLS 
 
Sl.No AGE SEX BMI T3(ng/dl) T4(ug/dl) TSH(uIU/mL) TC TG LDL HDL
1 26 1 23 88 9.8 1.3 176 97 96 43 
2 39 1 22 126 11.2 2.65 152 136 117 60 
3 50 1 20 94 7.21 4 179 126 103 46 
4 48 1 22 132 6.95 1.53 170 108 88 37 
5 44 1 23 112 7.6 2.31 151 137 117 53 
6 47 1 22 96 9.7 4.2 139 127 115 38 
7 15 1 21 146 9.97 0.89 162 104 107 57 
8 50 1 20 135 7.99 4.11 144 113 124 47 
9 28 1 21 176 11.51 2.25 179 138 126 49 
10 45 1 23 128 6.86 3.53 220 224 150 38 
11 22 1 26 89 9 2.12 167 146 120 36 
12 33 1 22 148 8.23 1.58 182 140 83 56 
13 50 1 19 123 8.63 1.11 194 104 118 62 
14 39 1 23 145 7.38 4.18 153 98 78 57 
15 49 1 23 88 10.17 3.4 177 138 95 44 
16 44 1 20 139 6.82 1.44 142 136 126 48 
17 48 1 22 78 9.1 3.99 196 128 98 47 
18 39 1 25 143 8.89 4.02 154 114 127 32 
19 49 1 21 89 7.34 2.88 132 149 114 44 
20 44 1 22 96 9.05 4.3 156 135 105 48 
21 47 1 22 112 11.26 2.6 153 105 86 52 
22 60 1 21 135 7.02 2.25 171 128 104 54 
23 58 1 23 185 9.76 3.6 172 94 124 64 
24 30 1 21 183 7.86 3.08 161 129 113 37 
25 48 1 20 165 6.51 2.61 148 134 124 49 
26 50 1 22 154 11.18 3.64 157 146 127 58 
27 52 1 22 98 7.24 4.2 178 101 74 70 
28 24 1 22 122 10.4 0.94 162 117 122 62 
29 45 1 21 94 5.88 1.36 199 140 127 66 
30 56 1 22 86 8.29 2.37 187 99 129 37 
31 20 1 21 123 9.56 3.45 148 116 117 71 
32 62 1 23 158 5.58 1.36 173 121 94 62 
33 54 1 23 160 6.74 1.09 135 126 108 30 
34 58 1 27 90 7.32 3.88 164 108 111 53 
35 34 1 22 104 11.15 2.84 168 149 75 63 
36 63 1 22 128 9.35 4.17 202 164 145 32 
37 53 1 20 110 6.37 1.37 160 139 88 46 
38 59 1 21 102 8.05 1.45 147 93 92 47 
39 55 1 25 128 7.85 2.78 155 125 106 34 
40 56 1 22 98 8.26 3.45 165 130 101 68 
 
 
 
 
KEY TO MASTERCHART 
Sex        
  Female      1           
  Male          2       
Symptoms 
Weight gain       Constipation 
  Present  1     Present  1 
  Absent  2     Absent   2 
Cold intolerance               Tiredness 
  Present  1                    Present  1 
  Absent   2                   Absent   2 
Depression     Musculoskeletal symptoms 
  Present  1     Present  1 
  Absent   2     Absent   2 
Menorrhagia                                                    Infertility 
                      Present   1                                          Present   1 
                      Absent    2                                         Absent    2 
Voice changes    Neck swelling   
           Present  1                                 Present      1 
                   Absent   2                                  Absent     2 
Asymptomatic                                    
                      Yes  1 
                       No  2 
Salt intake 
                    Iodised    1 
                   Non iodised  2 
PAST HISTORY 
Hypertension                      Diabetes mellitus                          IHD 
           Present 1                              Present 1                         Present 1  
            Absent   2                             Absent  2                         Absent    2 
Thyroidectomy                    Hyperthyroidism 
      Present   1                            Present  1 
     Absent     2                          Absent  2 
HISTORY OF DRUG INTAKE 
1.Lithium     2.Amiodarone   3. Antithyroid drugs 4.Radioiodine 
5.Interferon 
                                         Yes   1              
                                         No    2             
 
SIGNS 
  Pulse                               Blood pressure                  Goitre          Dry skin        
    Normal        1                Normal           1                Yes  1          Yes 1  
    Bradycardia 2                Hypertension  2                No   2           No 2 
Puffy eyes                          Delayed relaxation of ankle jerk 
    Yes 1                                Yes 1                                     
     No 2                                 No 2 
INVESTIGATIONS 
Fasting blood sugar(FBS)                            TPO antibody 
        Normal     1                                              Positive   1                                                 
        High          2                                             Negative  2      
Levothyroxine(LT4) treatment 
        Started            1 
        Not started      2               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX III 
 
ETHICAL COMMITTEE APPROVAL 
 
 
 
 
 
 
APPENDIX IV 
 
ABBREVIATIONS 
 
BMI   - Body mass index 
BP- Blood pressure 
CHD   -  Coronary heart disease 
DRAJ- Delayed relaxation of ankle jerk 
FBS –Fasting blood sugar 
HDL   -  High density lipoprotein 
I Q     -  Intelligence quotient 
LDL  -   Low density lipoprotein 
PAF   - Platelet activating factor 
PAF- AH- Platelet activating factor acetyl hydrolase 
RAI- Radio active iodine 
T3  - Total triiodothyronine 
T4 – Total thyroxine 
fT4- Free thyroxine 
TSH – Thyroid stimulating hormone 
TRH – Thyrotropin releasing hormone 
TPO – Thyroid peroxidase 
TC – Total cholesterol 
TG - Triglycerides 
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SIGNS ON CLINICAL EXAMINATION 
Fig 7   
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